Cargando…

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials

AIM: To assess the impact of pre‐specified patient characteristics on efficacy and safety of subcutaneous tanezumab in patients with osteoarthritis (OA). METHODS: Data were pooled from two (efficacy; N = 1545) or three (safety; N = 1754) phase 3 placebo‐controlled trials. Change from baseline to wee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berenbaum, Francis, Schnitzer, Thomas, Kivitz, Alan, Viktrup, Lars, Johnston, Elizabeth, Yang, Ruoyong, Whalen, Ed, Tive, Leslie, Semel, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285028/ https://www.ncbi.nlm.nih.gov/pubmed/34626502 http://dx.doi.org/10.1111/ijcp.14975

Ejemplares similares

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials
por: Berenbaum, Francis, et al.
Publicado: (2022)

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis
por: Schnitzer, Thomas J., et al.
Publicado: (2021)

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018)

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
por: Berenbaum, Francis, et al.
Publicado: (2021)

Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
por: Tive, Leslie, et al.
Publicado: (2019)

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
por: Markman, John D., et al.
Publicado: (2022)

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
por: Berenbaum, Francis, et al.
Publicado: (2020)

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab
por: Hunter, D.J., et al.
Publicado: (2022)

Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis
por: Birbara, Charles, et al.
Publicado: (2018)

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
por: Neogi, Tuhina, et al.
Publicado: (2022)

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis
por: Conaghan, Philip G., et al.
Publicado: (2022)

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
por: Markman, John D., et al.
Publicado: (2020)

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Factors associated with physician-reported treatment status of patients with osteoarthritis pain
por: Schnitzer, Thomas J., et al.
Publicado: (2022)

Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States
por: Robinson, Rebecca L., et al.
Publicado: (2022)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Pooled Analysis of Tanezumab Efficacy and Safety with Subgroup Analyses of Phase III Clinical Trials in Patients with Osteoarthritis Pain of the Knee or Hip [Corrigendum]
Publicado: (2020)

Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies
por: Miki, Kenji, et al.
Publicado: (2022)

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety
por: Schmelz, Martin, et al.
Publicado: (2019)

Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis
por: Hu, Rui, et al.
Publicado: (2021)

Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials
por: Zhang, Bocheng, et al.
Publicado: (2021)

Nerve Growth Factor Signaling and Its Contribution to Pain
por: Barker, Philip A, et al.
Publicado: (2020)

Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United States
por: Nalamachu, Srinivas R, et al.
Publicado: (2020)

Tanezumab: Finally a Monoclonal Antibody for Pain Relief
por: Nair, Abhijit S
Publicado: (2018)

Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis
por: Patel, Mona K., et al.
Publicado: (2018)

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain
por: Walicke, Patricia A., et al.
Publicado: (2018)

Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor
por: Shoji, Satoshi, et al.
Publicado: (2023)

Tanezumab: a selective humanized mAb for chronic lower back pain
por: Webb, Michael P, et al.
Publicado: (2018)

Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial
por: Markman, John, et al.
Publicado: (2018)

The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial
por: Dakin, Paula, et al.
Publicado: (2019)

Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis: A Mediation-Modeling Approach
por: Abraham, Lucy, et al.
Publicado: (2023)

Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender
por: Walmsley, Sharon, et al.
Publicado: (2017)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Disparities across Diverse Populations in the Health and Treatment of Patients with Osteoarthritis
por: Faison, Warachal E., et al.
Publicado: (2021)

Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients
por: Tahir, Sophia, et al.
Publicado: (2023)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials
por: Zhao, Di, et al.
Publicado: (2022)

New horizons and perspectives in the treatment of osteoarthritis
por: Berenbaum, Francis
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_b1r69oh1j744aombdc4rmc69lu